Mutlu Keskin1, Hanna Lähteenmäki2, Nilminie Rathnayake2, Ismo T Räisänen2, Taina Tervahartiala2, Pirjo Pärnänen2, Ahmet Murat Şenışık3, Didem Karaçetin4, Ayben Yentek Balkanay4, Pia Heikkilä2, Jaana Hagström5,6,7, Jaana Rautava2,5,8, Caj Haglund7,9, Ulvi Kahraman Gursoy10, Angelika Silbereisen11, Nagihan Bostanci11, Timo Sorsa2,11. 1. Oral and Dental Health Department, Altınbaş University , İstanbul, Turkey. 2. Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki University Hospital , Helsinki, Finland. 3. Radiotherapy Department, Altınbaş University , İstanbul, Turkey. 4. Radiation Oncology Department, Başakşehir Çam and Sakura City Hospital , İstanbul, Turkey. 5. Department of Oral Pathology and Radiology, University of Turku , Turku, Finland. 6. Department of Pathology HUSLAB, Helsinki University Hospital , Helsinki, Finland. 7. Research Programs Unit, Translational Cancer Medicine, University of Helsinki , Helsinki, Finland. 8. Department of Pathology, HUSLAB & University of Helsinki , Helsinki, Finland. 9. Department of Surgery, University of Helsinki and Helsinki University Hospital , Helsinki, Finland. 10. Department of Periodontology, Institute of Dentistry, University of Turku , Turku, Finland. 11. Section of Periodontology and Dental Prevention, Division of Oral Diseases, Department of Dental Medicine , Karolinska Institutet, Sweden.
Abstract
Background: This cohort study investigated the role of the active matrix metalloproteinase-8 (aMMP-8) and interleukin-6 (IL-6) as oral fluid biomarkers for monitoring the periodontal degeneration occurring in head and neck cancer (HNC) patients treated by radiotherapy. Research design and methods: Eleven patients, aged 28-74, diagnosed with HNC were included in the study. Complete periodontal and oral examinations were performed pre-radiotherapy and 1 month after radiotherapy. Mouthrinse samples (pre-radiotherapy, after 6 weeks of radiotherapy and 1 month after radiotherapy) were assayed by aMMP-8 point-of-care-kit (PerioSafe®/ORALyzer®) for aMMP-8 and ELISA for IL-6. Results: HNC radiotherapy had a deteriorating impact on the periodontium and a significant impact on periodontal biomarkers aMMP-8 and IL-6 and increased their levels in mouthrinse. Clinical-attachment-loss (CAL) (site of greatest loss: mean = 1.7 mm, range = 1-3 mm) corresponding to rapid progression of periodontitis. There was a positive repeated measures correlation (rmcorr = 0.667) between the aMMP-8 and IL-6 levels. Conclusions: Elevated aMMP-8 levels were observed 1 month after radiotherapy among some HNC patients suggesting a prolonged increased susceptibility to further periodontal tissue destruction. Currently available aMMP-8 point-of-care testing could be useful to monitor and assess quantitatively online and real-time the risk of deterioration of periodontal health during HNC radiotherapy.
Background: This cohort study investigated the role of the active matrix metalloproteinase-8 (aMMP-8) and interleukin-6 (IL-6) as oral fluid biomarkers for monitoring the periodontal degeneration occurring in head and neck cancer (HNC) patients treated by radiotherapy. Research design and methods: Eleven patients, aged 28-74, diagnosed with HNC were included in the study. Complete periodontal and oral examinations were performed pre-radiotherapy and 1 month after radiotherapy. Mouthrinse samples (pre-radiotherapy, after 6 weeks of radiotherapy and 1 month after radiotherapy) were assayed by aMMP-8 point-of-care-kit (PerioSafe®/ORALyzer®) for aMMP-8 and ELISA for IL-6. Results: HNC radiotherapy had a deteriorating impact on the periodontium and a significant impact on periodontal biomarkers aMMP-8 and IL-6 and increased their levels in mouthrinse. Clinical-attachment-loss (CAL) (site of greatest loss: mean = 1.7 mm, range = 1-3 mm) corresponding to rapid progression of periodontitis. There was a positive repeated measures correlation (rmcorr = 0.667) between the aMMP-8 and IL-6 levels. Conclusions: Elevated aMMP-8 levels were observed 1 month after radiotherapy among some HNC patients suggesting a prolonged increased susceptibility to further periodontal tissue destruction. Currently available aMMP-8 point-of-care testing could be useful to monitor and assess quantitatively online and real-time the risk of deterioration of periodontal health during HNC radiotherapy.
Entities:
Keywords:
Il-6; aMMP-8; head and neck cancer; periodontitis; point of care technology; radiotherapy
Authors: Rajesh V Lalla; Nathaniel S Treister; Thomas P Sollecito; Brian L Schmidt; Lauren L Patton; Erika S Helgeson; Alexander Lin; Cynthia Rybczyk; Robert Dowsett; Upendra Hegde; Timothy S Boyd; Thomas G Duplinsky; Michael T Brennan Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2022-01-31
Authors: Ismo T Räisänen; Hanna Lähteenmäki; Shipra Gupta; Andreas Grigoriadis; Vaibhav Sahni; Juho Suojanen; Hanna Seppänen; Taina Tervahartiala; Dimitra Sakellari; Timo Sorsa Journal: Diagnostics (Basel) Date: 2021-04-15
Authors: Hanna Lähteenmäki; Taina Tervahartiala; Ismo T Räisänen; Pirjo Pärnänen; Matti Mauramo; Shipra Gupta; Victoria Sampson; Nilminie Rathnayake; Anna-Maria Heikkinen; Saeed Alassiri; Dirk-Rolf Gieselmann; Roland Frankenberger; Timo Sorsa Journal: Clin Exp Dent Res Date: 2022-02-03